BAR HARBOR — Scientists at the MDI Biological Laboratory and Novo Biosciences have identified a drug candidate to restore heart muscle function following a heart attack.
Their research on the role of MSI-1436 in regenerating heart muscle tissue in zebrafish and mice was described in a paper in the peer-reviewed journal “npj Regenerative Medicine.”
Cardiovascular disease is the world’s leading killer, taking the lives of 17.5 million people annually, according to the World Health Organization, and disabling millions more. Currently, no drug exists to restore heart muscle function after a heart attack.
“The potential impact of MSI-1436 is enormous,” said Viravuth P. Yin of the lab, one of the paper’s authors, said. “If it shows similar results in humans, it will be a game-changer for patients who suffer a heart attack and/or are living with heart disease.”
The institution seeks to move the drug into human clinical trials through its spinoff company Novo Biosciences. The next step is to test the drug in pigs, the animal whose heart most closely resembles that of humans.
The drug has two advantages that are expected to smooth the path to the clinic. First, MSI-1436 stimulates tissue regeneration in both zebrafish and mice, which are separated by approximately 450 million years of evolution. This increases the likelihood it will have a comparable effect in humans too. Second, it already has been shown to be well tolerated by patients in Phase 1 and 1b clinical trials for an unrelated indication. The maximum well-tolerated human dose is five to 50 times higher than the dose shown to be effective in stimulating heart repair in zebrafish and mice.
“The previous clinical trials of MSI-1436 make a big difference in bringing this drug to market,” said Kevin Strange, president of the MDI Biological Laboratory and one of the paper’s authors.
“The path from laboratory bench to patient bedside can be long and difficult. But the fact that MSI-1436 has been shown to be safe for use in humans shaves years off the drug development process.”
Strange also is the CEO and cofounder of Novo Biosciences and the co-inventor of MSI-1436, along with Yin and collaborator Michael A. Zasloff. Yin is the cofounder and chief scientific officer of Novo Biosciences. The scientists have been issued a patent on the use the drug for the treatment of heart disease.
The original research on MSI-1436 was conducted by Yin in zebrafish, an organism that can regenerate the form and function of almost any body part. He found that the administration of the drug increased appendage regeneration by 200 to 300 percent. Follow-up research showed that it also stimulated zebrafish heart regeneration to the same degree.
“That was definitely a ‘Eureka!’ moment,” Yin said of the day in the laboratory when the appendage study was conducted. He was so astonished by the results that he repeated the study several times and under different conditions.
Yin followed the studies in zebrafish with studies in adult mice, which, like humans, have a limited capacity for regeneration. The goal was to see if MSI-1436 could stimulate regeneration in higher organisms. Though mammals such as mice and humans share the genetic pathways for regeneration with zebrafish, they have been largely deactivated for reasons that are still unclear.
The results in mice, which are detailed in the paper, show that the administration of MSI-1436 24 hours after an artificially induced heart attack increased survival, improved heart function two- to three-fold, reduced the size of the infarct or scar tissue by 53 percent; reduced ventricular wall thinning and stimulated heart muscle cell proliferation in the infarct border zone by six-fold.
When a patient suffers a heart attack, part of the heart muscle dies, and the associated scarring interferes with the heart’s ability to effectively pump blood. The authors believe MSI-1436 to be the first drug candidate that has been shown to reduce scarring and induce heart regeneration in an adult mammal.
Strange and Yin view their MSI-1436 results as a validation of the MDI Biological Laboratory’s and Novo Biosciences’ unique approach to regenerative medicine. Regenerative medicine has focused on complex stem cell, gene and tissue-engineering approaches for the last 15 years or more, but thus far, these approaches have failed to deliver on their promise, despite the investment of hundreds of millions of dollars.
By contrast, MDI Biological Laboratory and Novo Biosciences scientists are focused on decoding the instruction manual for repair and regeneration that has been conserved by evolution in human DNA for hundreds of millions of years. This approach has been very effective: in only a few years and at modest cost, they have identified three potential regenerative medicine drugs.
“If we can decode the instruction manual for regeneration in highly regenerative species,” Yin said, “we can use drug therapies to reignite our own dormant regenerative capacity. Our research in these highly regenerative species is showing that regenerating damaged or lost tissues and organs could be as simple as taking a drug.”
MSI-1436 also has potential applications for the regeneration of skeletal muscle tissue in Duchenne muscular dystrophy, which is characterized by progressive muscle degeneration and untimely death due to heart and/or respiratory failure. Other potential applications include stimulation of wound healing and regeneration of multiple other tissues, including nervous tissue.
The research was supported by Center for Biomedical Research Excellence (COBRE) and Institutional Development Award (IDeA) grants from the National Institute of General Medical Sciences, part of the National Institutes of Health. Additional support was provided by a grant from the Maine Technology Institute, by an American Heart Association Scientist Development Grant and by private philanthropy.